Human Immunodeficiency Virus Type-1 (HIV-1) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1067438
  • December 2021
  • Pharmaceuticals
  • 125 Pages
Report Description

This report is a comprehensive study that examines the Human Immunodeficiency Virus Type-1 (HIV-1) industry in depth. With reference to key regions and major nations, the study specifies the product type of Human Immunodeficiency Virus Type-1 (HIV-1) as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Human Immunodeficiency Virus Type-1 (HIV-1) market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Human Immunodeficiency Virus Type-1 (HIV-1) market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.

The top vendors and distributors operating in all of the major regions have also been highlighted in the Human Immunodeficiency Virus Type-1 (HIV-1) market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
 
Human Immunodeficiency Virus Type-1 (HIV-1) Market Strategic Analysis 

The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Human Immunodeficiency Virus Type-1 (HIV-1) market study. The market dynamics and factors such as the threat of a Human Immunodeficiency Virus Type-1 (HIV-1) substitute, the threat of new entrants into the Human Immunodeficiency Virus Type-1 (HIV-1) market, buyer bargaining power, supplier bargaining power to Human Immunodeficiency Virus Type-1 (HIV-1) providing companies, and internal rivalry among Human Immunodeficiency Virus Type-1 (HIV-1) providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.

This analysis assists report users in evaluating the Human Immunodeficiency Virus Type-1 (HIV-1) market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Human Immunodeficiency Virus Type-1 (HIV-1) industry.
 
Human Immunodeficiency Virus Type-1 (HIV-1) Market Key Trends Analysis

The important factors influencing the growth of the Human Immunodeficiency Virus Type-1 (HIV-1) market have been examined in this report. The driving factors that are boosting demand for Human Immunodeficiency Virus Type-1 (HIV-1)s and the restraining factors that are slowing growth of the Human Immunodeficiency Virus Type-1 (HIV-1) industry are addressed in depth, as well as their implications for the worldwide Human Immunodeficiency Virus Type-1 (HIV-1) market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.

Human Immunodeficiency Virus Type-1 (HIV-1) Market Key Segment Analysis

By segmenting the market by product type, application, and geography, the study provides a clear picture of the Human Immunodeficiency Virus Type-1 (HIV-1) industry. On the basis of current and future trends, all segments of the Human Immunodeficiency Virus Type-1 (HIV-1) industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.

The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.

The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
 
Human Immunodeficiency Virus Type-1 (HIV-1) Market Regional Trends and Market Player’s Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Human Immunodeficiency Virus Type-1 (HIV-1) market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Human Immunodeficiency Virus Type-1 (HIV-1) market throughout the projected period.


 
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Human Immunodeficiency Virus Type-1 (HIV-1) market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Human Immunodeficiency Virus Type-1 (HIV-1) market. All important stakeholders in the Human Immunodeficiency Virus Type-1 (HIV-1) value chain and technological ecosystem are expected to benefit from the insights offered in the Human Immunodeficiency Virus Type-1 (HIV-1) market research study.

In order to provide a broader understanding of the top competitors in the Human Immunodeficiency Virus Type-1 (HIV-1) market, the research includes a company market share analysis. Aelix Therapeutics, CytoDyn, Frontier Biotechnologies, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Merck Sharp & Dohme Corp, Mylan Laboratories Limited, National Institute of Allergy and Infectious Diseases, Sanofi, TaiMed Biologics Inc., Theratechnologies Inc., United Biopharma, ViiV Healthcare are among the major participants in the global Human Immunodeficiency Virus Type-1 (HIV-1) industry.
 
Scope of the report
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2021
Forecast Period Covered 2021-2028
Units for value Revenue in USD million and CAGR from 2021 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Aelix Therapeutics, CytoDyn, Frontier Biotechnologies, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Merck Sharp & Dohme Corp, Mylan Laboratories Limited, National Institute of Allergy and Infectious Diseases, Sanofi, TaiMed Biologics Inc., Theratechnologies Inc., United Biopharma, ViiV Healthcare
 
Major Highlights of the Human Immunodeficiency Virus Type-1 (HIV-1) Market report study:
  • An in-depth examination of the global Human Immunodeficiency Virus Type-1 (HIV-1) industry will be published soon.
  • The study examines the global Human Immunodeficiency Virus Type-1 (HIV-1) market and offers major actionable information to its players.
  • The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
  • The report study is expected to aid the industry's key decision-makers in their decision-making process.
  • Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
  • The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Human Immunodeficiency Virus Type-1 (HIV-1) industry.
  • The Market Ecosystem and Adoption in Different Markets
  • The global Human Immunodeficiency Virus Type-1 (HIV-1) market is being shaped by several major trends.
  • The size of the Human Immunodeficiency Virus Type-1 (HIV-1) market in terms of revenue has been measured in the past and will be measured in the future in USD million.
  • Consumer preference patterns and recent industrial developments
  • The worldwide Human Immunodeficiency Virus Type-1 (HIV-1) market's competitive landscape and player positioning analysis
  • Major players' key goods and solutions, as well as their business strategies
  • Recommendations for new market entrants as well as existing market participants.
  • The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
  • Operating players in the market encounter a number of significant hurdles.
  • An examination of the major risks involved in market operations
 
The report segment of the global Human Immunodeficiency Virus Type-1 (HIV-1) market as follows:
Global Human Immunodeficiency Virus Type-1 (HIV-1) Market: By Product Type

  • Type I
  • Type II
  • Type III

Global Human Immunodeficiency Virus Type-1 (HIV-1) Market: By Application
  • Application I
  • Application II
  • Application III

Global Human Immunodeficiency Virus Type-1 (HIV-1) Market: By Region
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China 
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The report study is drafted to provide actionable insights to the following mentioned audience:
  • Institutes of research and consulting firms
  • Companies are attempting to get into the Human Immunodeficiency Virus Type-1 (HIV-1) market.
  • Universities and students
  • Other companies in the Human Immunodeficiency Virus Type-1 (HIV-1) market include solution providers, product producers, service providers, and others.
  • Private companies and government agencies that are linked
  • Individuals interested in learning more about the Human Immunodeficiency Virus Type-1 (HIV-1) market

Manufacturers and Segments

  • Aelix Therapeutics
  • CytoDyn
  • Frontier Biotechnologies
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
  • Merck
  • Merck Sharp & Dohme Corp
  • Mylan Laboratories Limited
  • National Institute of Allergy and Infectious Diseases
  • Sanofi
  • TaiMed Biologics Inc.
  • Theratechnologies Inc.
  • United Biopharma
  • ViiV Healthcare
  • Type I
  • Type II
  • Type III
  • Application I
  • Application II
  • Application III

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Snapshot
          2.1.1. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market By Type I,2019
               2.1.1.1.
               2.1.1.2.Type I I
               2.1.1.3.Type I II
          2.1.2. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market By Application I,2019
               2.1.2.1.
               2.1.2.2.Application I I
               2.1.2.3.Application I II
          2.1.3. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market By End-use,2019
          2.1.4. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market By Geography,2019

3. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Type I, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type I, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type I, 2020
     4.2. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Type I, 2018 – 2028

5. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Application I, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application I, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application I, 2020
     5.2. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Application I, 2018 – 2028

6. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By End-use, 2018 – 2028

7. Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Analysis, 2018 – 2028 
          7.2.1. North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Type I, 2018 – 2028
          7.2.3. North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Application I, 2018 – 2028
          7.2.4. North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Analysis, 2018 – 2028 
          7.3.1.  Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Type I, 2018 – 2028
          7.3.3. Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Application I, 2018 – 2028
          7.3.4. Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Type I, 2018 – 2028
          7.4.3. Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Application I, 2018 – 2028
          7.4.4. Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Type I, 2018 – 2028
          7.5.3. Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Application I, 2018 – 2028
          7.5.4. Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Human Immunodeficiency Virus Type I-1 (HIV-1) Market Analysis, 2018 – 2028 
          7.6.1.  MEA Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Type I, 2018 – 2028
          7.6.3. MEA Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By Application I, 2018 – 2028
          7.6.4. MEA Human Immunodeficiency Virus Type I-1 (HIV-1) Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Human Immunodeficiency Virus Type I-1 (HIV-1) Providers
        8.4.1 Aelix Therapeutics
                8.4.1.1 Business Description
                8.4.1.2 Aelix Therapeutics Geographic Operations
                8.4.1.3 Aelix Therapeutics Financial Information
                8.4.1.4 Aelix Therapeutics Product Positions/Portfolio
                8.4.1.5 Aelix Therapeutics Key Developments
        8.4.2 CytoDyn
                8.4.2.1 Business Description
                8.4.2.2 CytoDyn Geographic Operations
                8.4.2.3 CytoDyn Financial Information
                8.4.2.4 CytoDyn Product Positions/Portfolio
                8.4.2.5 CytoDyn Key Developments
        8.4.3 Frontier Biotechnologies
                8.4.3.1 Business Description
                8.4.3.2 Frontier Biotechnologies Geographic Operations
                8.4.3.3 Frontier Biotechnologies Financial Information
                8.4.3.4 Frontier Biotechnologies Product Positions/Portfolio
                8.4.3.5 Frontier Biotechnologies Key Developments
        8.4.4 Gilead Sciences, Inc.
                8.4.4.1 Business Description
                8.4.4.2 Gilead Sciences, Inc. Geographic Operations
                8.4.4.3 Gilead Sciences, Inc. Financial Information
                8.4.4.4 Gilead Sciences, Inc. Product Positions/Portfolio
                8.4.4.5 Gilead Sciences, Inc. Key Developments
        8.4.5 GlaxoSmithKline
                8.4.5.1 Business Description
                8.4.5.2 GlaxoSmithKline Geographic Operations
                8.4.5.3 GlaxoSmithKline Financial Information
                8.4.5.4 GlaxoSmithKline Product Positions/Portfolio
                8.4.5.5 GlaxoSmithKline Key Developments
        8.4.6 Janssen Pharmaceuticals
                8.4.6.1 Business Description
                8.4.6.2 Janssen Pharmaceuticals Geographic Operations
                8.4.6.3 Janssen Pharmaceuticals Financial Information
                8.4.6.4 Janssen Pharmaceuticals Product Positions/Portfolio
                8.4.6.5 Janssen Pharmaceuticals Key Developments
        8.4.7 Merck
                8.4.7.1 Business Description
                8.4.7.2 Merck Geographic Operations
                8.4.7.3 Merck Financial Information
                8.4.7.4 Merck Product Positions/Portfolio
                8.4.7.5 Merck Key Developments
        8.4.8 Merck Sharp & Dohme Corp
                8.4.8.1 Business Description
                8.4.8.2 Merck Sharp & Dohme Corp Geographic Operations
                8.4.8.3 Merck Sharp & Dohme Corp Financial Information
                8.4.8.4 Merck Sharp & Dohme Corp Product Positions/Portfolio
                8.4.8.5 Merck Sharp & Dohme Corp Key Developments
        8.4.9 Mylan Laboratories Limited
                8.4.9.1 Business Description
                8.4.9.2 Mylan Laboratories Limited Geographic Operations
                8.4.9.3 Mylan Laboratories Limited Financial Information
                8.4.9.4 Mylan Laboratories Limited Product Positions/Portfolio
                8.4.9.5 Mylan Laboratories Limited Key Developments
        8.4.10 National Institute of Allergy and Infectious Diseases
                8.4.10.1 Business Description
                8.4.10.2 National Institute of Allergy and Infectious Diseases Geographic Operations
                8.4.10.3 National Institute of Allergy and Infectious Diseases Financial Information
                8.4.10.4 National Institute of Allergy and Infectious Diseases Product Positions/Portfolio
                8.4.10.5 National Institute of Allergy and Infectious Diseases Key Developments
        8.4.11 Sanofi
                8.4.11.1 Business Description
                8.4.11.2 Sanofi Geographic Operations
                8.4.11.3 Sanofi Financial Information
                8.4.11.4 Sanofi Product Positions/Portfolio
                8.4.11.5 Sanofi Key Developments
        8.4.12 TaiMed Biologics Inc.
                8.4.12.1 Business Description
                8.4.12.2 TaiMed Biologics Inc. Geographic Operations
                8.4.12.3 TaiMed Biologics Inc. Financial Information
                8.4.12.4 TaiMed Biologics Inc. Product Positions/Portfolio
                8.4.12.5 TaiMed Biologics Inc. Key Developments
        8.4.13 Theratechnologies Inc.
                8.4.13.1 Business Description
                8.4.13.2 Theratechnologies Inc. Geographic Operations
                8.4.13.3 Theratechnologies Inc. Financial Information
                8.4.13.4 Theratechnologies Inc. Product Positions/Portfolio
                8.4.13.5 Theratechnologies Inc. Key Developments
        8.4.14 United Biopharma
                8.4.14.1 Business Description
                8.4.14.2 United Biopharma Geographic Operations
                8.4.14.3 United Biopharma Financial Information
                8.4.14.4 United Biopharma Product Positions/Portfolio
                8.4.14.5 United Biopharma Key Developments
        8.4.15 ViiV Healthcare
                8.4.15.1 Business Description
                8.4.15.2 ViiV Healthcare Geographic Operations
                8.4.15.3 ViiV Healthcare Financial Information
                8.4.15.4 ViiV Healthcare Product Positions/Portfolio
                8.4.15.5 ViiV Healthcare Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Human Immunodeficiency Virus Type I-1 (HIV-1): Market Segmentation 
FIG. 2 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market, By Type I, 2019 (US$ Mn) 
FIG. 5 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market, By Application I, 2019 (US$ Mn) 
FIG. 6 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Human Immunodeficiency Virus Type I-1 (HIV-1) Providers, 2019
FIG. 11 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue Contribution, By Type I, 2019 & 2028 (Value %) 
FIG. 12 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue Contribution, By Application I, 2019 & 2028 (Value %) 
FIG. 13 Global Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Human Immunodeficiency Virus Type I-1 (HIV-1) Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Human Immunodeficiency Virus Type I-1 (HIV-1) market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Human Immunodeficiency Virus Type-1 (HIV-1) Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment1, 2018 – 2028
TABLE  North America Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment2, 2018 – 2028
TABLE  North America Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Country, 2018 – 2028
TABLE  Europe Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment1, 2018 – 2028
TABLE  Europe Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment2, 2018 – 2028
TABLE  Europe Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Country, 2018 – 2028
TABLE  Latin America Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Country, 2018 – 2028
TABLE  MEA Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment1, 2018 – 2028
TABLE  MEA Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Segment2, 2018 – 2028
TABLE  MEA Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, By Country, 2018 – 2028
TABLE  Aelix Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CytoDyn: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Frontier Biotechnologies: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Gilead Sciences, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Janssen Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck Sharp & Dohme Corp: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Mylan Laboratories Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  National Institute of Allergy and Infectious Diseases: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  TaiMed Biologics Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Theratechnologies Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  United Biopharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ViiV Healthcare: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Human Immunodeficiency Virus Type-1 (HIV-1) Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Human Immunodeficiency Virus Type-1 (HIV-1) Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Human Immunodeficiency Virus Type-1 (HIV-1) Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Human Immunodeficiency Virus Type-1 (HIV-1) Market, By Geography, 2019 (US$ Mn)
FIG.  Global Human Immunodeficiency Virus Type-1 (HIV-1) Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Human Immunodeficiency Virus Type-1 (HIV-1) Providers, 2016
FIG.  Global Human Immunodeficiency Virus Type-1 (HIV-1) Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Type I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type III Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Human Immunodeficiency Virus Type-1 (HIV-1) Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Application I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application III Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Human Immunodeficiency Virus Type-1 (HIV-1) Market Value, 2018 – 2028, (US$ Mn)